Shots:
The EC has approved Tuyory, a biosimilar version of RoActemra (Tocilizumab) across the EEA countries
Tuyory (tocilizumab) inhibits IL-6 signaling and is indicated for rheumatoid arthritis, juvenile idiopathic arthritis (including polyarthritis), giant cell arteritis, cytokine release syndrome, and COVID-19. It is available in both IV and SC forms, with dosing and presentations matching the reference product
Tuyory was co-developed by Gedeon Richter and Mochida Pharmaceutical …
